QUOTE AND NEWS
SeekingAlpha  5 hrs ago  Comment 
By Spencer Osborne: July of 2014 marked the "re-launch" of the anti-obesity drug Belviq from Arena Pharmaceuticals (NASDAQ:ARNA) and marketing partner Eisai (OTCPK:ESALY). Belviq had its initial launch in June of 2013 and sales during the first...
SeekingAlpha  9 hrs ago  Comment 
SeekingAlpha  Aug 15  Comment 
By Spencer Osborne: The FDA Adverse Events raw data for Q4 of 2013 have been released, and while the exact information relating to the nature of adverse events will take some time to make its way to the public, it is possible to search through the...
SeekingAlpha  Aug 4  Comment 
By Spencer Osborne: Arena Pharmaceuticals (NASDAQ:ARNA) beat the street by an impressive $0.14 per share. Some investors were thrilled with the news, but more experienced investors saw the quarter for what it was and removed the one-time event to...
SeekingAlpha  Aug 1  Comment 
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Q2 2014 Earnings Conference Call August 01, 2014 8:30 a.m. ET Executives Robert E. Hoffman – SVP, Finance and CFO Jack Lief – Co-Founder, Chairman, President and CEO Craig M. Audet –...
Forbes  Jul 30  Comment 
When Arena Pharmaceuticals reports its second quarter results on Friday, August 1, 2014, analysts are anticipating a drop into the red. They are expecting a loss of 11 cents a share after the company booked a profit of 17 cents a year...
SeekingAlpha  Jul 28  Comment 
By Spencer Osborne: Arena Pharmaceuticals (NASDAQ:ARNA) will be hosting its quarterly conference call on Friday, August 1st, 2014 at 8:00 AM Eastern time. This particular call carries a pretty substantial importance for an equity that has...
SeekingAlpha  Jul 25  Comment 
By Spencer Osborne: Sales of the anti-obesity drug, Belviq, from Arena Pharmaceuticals (NASDAQ:ARNA) seem to be trying to buck the trend in seasonality in the anti-obesity sector. As a relatively new product on the market, we should anticipate...
StreetInsider.com  Jul 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Arena+Pharma+%28ARNA%29+Enters+into+BELVIQ+Marketing+Agreement+in+Israel/9674520.html for the full story.
SeekingAlpha  Jul 18  Comment 
By Spencer Osborne: This week, we saw an anticipated pop in prescription numbers for the anti-obesity pill Belviq from Arena Pharmaceuticals (NASDAQ:ARNA). A nice week-over-week climb was expected, considering that the last data we saw fell in...
SeekingAlpha  Jul 16  Comment 
By Spencer Osborne: Arena Pharmaceuticals (NASDAQ:ARNA) has announced that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators" by the United States Patent and Trademark Office, for APD371, an agonist of the...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki